Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-06-18 02:02 UTC

BIOMED PULSE

June 18, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has surpassed 676 confirmed cases and 136 deaths as of June 10, making it the dominant global health emergency of the moment. [1] Mood: urgent on outbreak front, cautiously active on longevity science and food safety.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) - DRC AND UGANDA

  • As of June 10, 2026, the DRC had reported 676 confirmed Ebola Bundibugyo virus (BVD) cases and 136 confirmed deaths; cross-border transmission to Uganda is ongoing and geographic spread inside DRC continues to accelerate. [1]
  • WHO declared the BVD outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, the first PHEIC for Bundibugyo virus disease; the IHR Emergency Committee confirmed it does not yet meet the higher threshold of a pandemic emergency. [2] [3]
  • Africa CDC and WHO launched a joint continental Ebola preparedness and response plan on June 5, 2026, seeking to raise USD 518 million to support African countries in their response. [4]
  • WHO expert groups convened in late May 2026 assessed candidate vaccines and therapeutics specifically for Bundibugyo virus disease, with no approved product yet in widespread use. [5]
  • CDC has activated enhanced Ebola airport screening at Washington-Dulles International Airport and Atlanta Hartsfield-Jackson, funneling travelers from DRC and Uganda through targeted health checks. [6] [7]

HANTAVIRUS (ANDES VIRUS) - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • As of the fourth WHO Disease Outbreak News report (May 28, 2026), the Andes hantavirus cluster linked to the M/V Hondius cruise ship has resulted in confirmed and suspected cases across multiple countries; the pathogen is Andes hantavirus, which is notable because it is the only hantavirus known to transmit person-to-person. [8]
  • WHO Director-General Tedros briefed media on May 7 noting 8 total cases at that point, including 3 deaths and 5 laboratory-confirmed hantavirus infections. [9]
  • Over 120 passengers from 23 countries were safely disembarked in Tenerife during the response operation; CDC provided rolling daily briefings from May 13-15 and a further update on May 19. [10] [11]

MPOX - GLOBAL CLADE Ib SITUATION

  • WHO's December 2025 Disease Outbreak News flagged broader local transmission of clade Ib MPXV among men who have sex with men (MSM) in countries previously reporting only travel-linked cases, signaling geographic widening. [12]
  • A February 2026 WHO DON reported two confirmed cases of a recombinant MPXV strain carrying genomic elements of both clade Ib and clade IIb, the product of co-infection and natural recombination in the same individual. [13]

NIPAH VIRUS - INDIA AND BANGLADESH

  • India's IHR Focal Point notified WHO on January 26, 2026, of two laboratory-confirmed Nipah virus (NiV) cases in healthcare workers at a private hospital in Barasat, North 24 Parganas district, West Bengal. [14]
  • Bangladesh reported one confirmed NiV case in Rajshahi Division on February 6, 2026; the patient developed fever and neurological symptoms beginning January 21, a classic Nipah presentation. [15]

FOOD-BORNE OUTBREAKS - CURRENT U.S. ALERTS

  • CDC warns of a Listeria monocytogenes outbreak linked to recalled chicken fettuccine alfredo meals, with 17 people confirmed sick from the same strain as of June 19, 2026. [16]
  • A separate ongoing Listeria outbreak is linked to requesón/soft ricotta cheese, posted June 5, 2026. [17]
  • CDC's Salmonella alert for pistachio cream involves four people sick with the same Salmonella strand, posted June 16, 2026. [18]
  • Backyard poultry-linked Salmonella has grown to 34 sick people across 13 states as of April 23, 2026, with over a quarter of cases in children under 5 years old in updated figures from May 14. [19] [20]

NEW WORLD SCREWWORM

  • CDC activated its Emergency Operations Center specifically for a New World Screwworm (Cochliomyia hominivorax) response on June 12, 2026, marking a notable parasitic threat. [21]

INFANT BOTULISM - FORMULA LINK

  • CDC updated its investigation of infant botulism cases on June 13, 2026, urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula. [22]

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE AND KIDNEY REPAIR

  • A Europe PMC study published June 14, 2026, found that AMD1-mediated polyamine metabolism governs the fate of tubular cells after kidney injury: when AMD1 activity is insufficient, tubular cells slip into senescence rather than repairing, potentially driving chronic kidney disease progression in older adults. [23]
  • A plain-language takeaway: polyamines (small molecules made by nearly all cells) appear to act as a brake on the senescence program in kidney tubules, suggesting polyamine pathway modulation as a potential anti-aging kidney target.

DNA METHYLATION, TELOMERE LENGTH, AND BRAIN ANEURYSM RISK

  • A genetic study published in IBRO Neuroscience Reports (May 30, 2026, Europe PMC) used Mendelian randomization to test whether DNA methylation-estimated biological age phenotypes and shorter telomere length causally raise risk of intracranial aneurysms. [24]
  • The study authors found evidence linking accelerated epigenetic aging and shorter telomeres to increased aneurysm risk, adding vascular brain aging to the list of outcomes tied to biological aging clocks.

COLLAGEN OXIDATION AND TISSUE AGING

  • A June 11, 2026, Europe PMC paper in Redox Reports examined both enzymatic and non-enzymatic oxidation of fibrillar collagen, the structural protein underpinning skin, bone, and connective tissue strength. [25]
  • Non-enzymatic oxidation, accelerated by reactive oxygen species accumulating with age, stiffens collagen fibers and impairs tissue repair, offering a mechanism for age-related frailty and wound healing decline.

GRIP STRENGTH AS A LONGEVITY BIOMARKER

  • A prospective parallel study published in Global Health Action (June 15, 2026) analyzed Chinese and European older adult cohorts and found that combined handgrip strength predicts incident chronic digestive diseases including liver and gastrointestinal conditions. [26]
  • The finding extends the utility of handgrip dynamometry beyond cardiovascular and mortality endpoints into GI aging, supporting it as a low-cost, broadband functional aging biomarker.

ANTI-OSTEOPOROSIS DRUGS AND FRACTURE HEALING

  • A systematic review and meta-analysis in Lancet Healthy Longevity found that anti-osteoporotic medications, including bisphosphonates and denosumab, do not impair fracture healing outcomes and may support bone repair in older adults. [27]
  • An accompanying editorial summarized the clinical message as: treat the bone disease, not the fear of interfering with healing. [28]

INTRINSIC CAPACITY AND DISABILITY BEFORE DEATH

  • A decedent cohort study in Lancet Healthy Longevity linked higher intrinsic capacity (the composite of cognitive, locomotor, sensory, vitality, and psychological domains defined by WHO) to less disability in the final years of life among older adults. [29]
  • A companion editorial noted the relationship is dynamic, meaning interventions to preserve intrinsic capacity at any age may compress the period of pre-death disability. [30]

MATERNAL DIET AND NEONATAL MICROBIOME

  • A June 9, 2026, paper in Gut Microbes showed that maternal diet during pregnancy shapes neonatal microbiome development and neurometabolic resilience in offspring, with early microbiome composition influencing long-term brain metabolite profiles. [31]
  • While not an aging study per se, the work extends the developmental origins of health and disease framework into longevity biology by linking prenatal nutrition to offspring neurological aging trajectories.

URIC ACID AND NEUROPROTECTION VIA Nrf2 / FERROPTOSIS PATHWAY

  • A June 4, 2026, Europe PMC study in Redox Reports showed uric acid alleviates neuroinflammation in LPS-stimulated BV2 microglial cells and in a mouse model of Parkinson's disease (MPTP-induced), operating through the Nrf2 signaling pathway to resist ferroptosis, an iron-dependent cell death mechanism implicated in neurodegenerative aging. [32]

💊 NEW CURES & APPROVALS

KEYTRUDA QLEX - MERCK SHARP DOHME

  • openFDA records a supplemental approval for KEYTRUDA QLEX (pembrolizumab plus berahyaluronidase alfa-PMPH, BLA761467) from Merck Sharp Dohme; the berahyaluronidase component enables subcutaneous delivery of the PD-1 immune checkpoint inhibitor pembrolizumab, broadening its cancer treatment convenience. [33]

KEYTRUDA (IV FORMULATION) - MERCK SHARP DOHME

  • A separate supplemental approval was recorded for the original intravenous KEYTRUDA (pembrolizumab, BLA125514), reflecting an additional indication or label update. [34]

WELIREG - MERCK SHARP DOHME

  • openFDA shows a supplemental approval for WELIREG (belzutifan, NDA215383), a HIF-2 alpha inhibitor used in VHL disease-associated tumors and renal cell carcinoma, expanding the anti-cancer toolkit for hypoxia-pathway-driven tumors. [35]

TRUQAP - ASTRAZENECA

  • Supplemental approval logged for TRUQAP (capivasertib, NDA218197) by AstraZeneca; capivasertib is an AKT kinase inhibitor used in combination for hormone receptor-positive, HER2-negative advanced breast cancer. [36]

YERVOY - BRISTOL MYERS SQUIBB

  • Supplemental approval recorded for YERVOY (ipilimumab, BLA125377); ipilimumab is a CTLA-4 checkpoint inhibitor used across multiple oncology indications including melanoma and non-small cell lung cancer. [37]

TZIELD - PROVENTION BIO

  • Supplemental approval logged for TZIELD (teplizumab-mzwv, BLA761183) by Provention Bio; teplizumab is an anti-CD3 monoclonal antibody that delays onset of Stage 3 type 1 diabetes by preserving beta-cell function. [38]

RINVOQ LQ - ABBVIE

  • Supplemental approval recorded for RINVOQ LQ (upadacitinib liquid formulation, NDA218347) by AbbVie; upadacitinib is a JAK1-selective inhibitor approved across rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis. [39]

EMPAGLIFLOZIN AND METFORMIN HCL GENERIC - AUROBINDO PHARMA

  • openFDA records an original tentative approval for Aurobindo Pharma's generic fixed-dose empagliflozin/metformin hydrochloride (ANDA212374), an SGLT2-inhibitor plus biguanide combination for type 2 diabetes management. [40]

🧪 CLINICAL TRIALS

FRAILTY IN CHILDHOOD CANCER SURVIVORS

  • NCT02256137 is a longitudinal study assessing frailty trajectories in young adult survivors of pediatric cancer, recognizing that cancer treatment accelerates biological aging and produces early-onset frailty in this population. [41]

CORTICAL MICROINFARCTIONS AND COGNITIVE AGING MRI TRIAL

  • NCT06218576 is comparing follow-up MRI sensitivity for acute cerebral and cerebellar cortical microinfarctions (CMI), tiny lesions frequently found in elderly patients with cognitive dysfunction; the study focuses on temporal MRI signal dynamics of these aging-linked lesions. [42]

AUTOLOGOUS TCR T CELL THERAPY FOR HEMATOLOGIC MALIGNANCIES WITH TP53/RAS MUTATIONS

  • NCT06904066 is testing autologous T cells transduced with retroviral vectors expressing T cell receptors (TCRs) targeting participant-specific neoantigens arising from TP53 or RAS mutations in blood cancers, a highly personalized immunotherapy approach. [43]

NEOANTIGEN TCR THERAPY IN PROSTATE CANCER ACTIVE SURVEILLANCE

  • NCT07574541 is evaluating a multitargeted recombinant Ad5 PSA/MUC-1/Brachyury vaccine (TriAdeno) combined with IL-15 superagonist N-803 in men with clinically localized prostate cancer on active surveillance, aiming to immunologically control low-grade disease. [44]

N-ACETYL-D-MANNOSAMINE (MANNAC) IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS

  • NCT06664814 is an open-label Phase 2 study of ManNAc, a sialic acid precursor, in primary focal segmental glomerulosclerosis (FSGS), a scarring kidney disease that can accelerate age-related kidney failure. [45]

BARICITINIB IN JOB SYNDROME (HIES) WITH LUPUS-LIKE DISEASE

  • NCT07262983 is evaluating safety and tolerability of baricitinib, a JAK1/2 inhibitor, in patients with autosomal dominant hyper-IgE syndrome (Job syndrome) presenting with lupus-like disease or atopic dermatitis. [46]

RISDIPLAM REAL-WORLD OUTCOMES IN SPINAL MUSCULAR ATROPHY

  • NCT07531719 is a 24-month prospective non-interventional study tracking real-world clinical outcomes, safety, and motor function in patients with Type I and Type II SMA receiving risdiplam, an SMN2 splice modifier. [47]

CURCUMIN BIOAVAILABILITY FORMULATION VAS-101 IN SICKLE CELL DISEASE

  • NCT07566494 is testing escalating doses of VAS-101, a bioavailable curcumin formulation, in adults with stable sickle cell disease, based on prior evidence that curcumin improves red blood cell health; the trial addresses the poor oral bioavailability that has limited standard curcumin use. [48]

EtCO2 MONITORING TO REDUCE HYPOXEMIA IN ELDERLY POST-SURGERY PATIENTS

  • NCT07652385 is a randomized controlled study of transnasal microstream end-tidal CO2 monitoring in the post-anesthesia care unit in elderly patients ages 65-80 after abdominal surgery, targeting postoperative hypoxemia, a common and dangerous complication in aging surgical patients. [49]

ACCEPTANCE AND COMMITMENT THERAPY VS. COGNITIVE BEHAVIOR THERAPY IN HIV/AIDS

  • NCT07652918 is a randomized controlled trial at Sheikh Zayed Hospital comparing ACT and CBT interventions in 72 HIV/AIDS adults ages 18-40 on antiretroviral therapy, measuring psychological distress, stigmatization, social support, and treatment adherence. [50]

📢 PUBLIC HEALTH

ACIP MEETING JUNE 25-26, 2025 OUTCOMES

  • CDC's Advisory Committee on Immunization Practices (ACIP) met June 25-26, 2025, and concluded with a joint statement; agenda topics included updated vaccine decision frameworks and immunization schedule changes. [51] [52]

IMMUNIZATION SCHEDULE: INDIVIDUAL-BASED COVID-19 DECISIONS AND STANDALONE CHICKENPOX VACCINATION

  • In October 2025, CDC updated its adult and child immunization schedules to apply individual-based decision-making for COVID-19 vaccination and to allow standalone varicella vaccination for toddlers, a shift away from universal mandates. [53]

DRUG-RESISTANT BACTERIA ON THE RISE

  • A September 2025 CDC report found a dramatic increase in dangerous drug-resistant bacteria across the United States, reinforcing antimicrobial resistance as a sustained public health crisis. [54]

CONGENITAL SYPHILIS AT 12-YEAR HIGH

  • New CDC data released September 24, 2025, showed U.S. cases of newborn syphilis increased for the 12th consecutive year in 2024, signaling persistent STI surveillance gaps. [55]

TICK BITE ER VISITS HIGHER THAN USUAL THIS SEASON

  • CDC data as of April 23, 2026, show weekly emergency room visits for tick bites are running higher than seasonal norms; Lyme disease and other tickborne diseases continue to expand geographically. [56]

UNSAFE FOOD KILLS 1.5 MILLION ANNUALLY GLOBALLY

  • A June 3, 2026, WHO report estimated unsafe food causes 866 million illnesses and 1.5 million deaths globally each year, with children under five facing nearly three times the risk of illness compared to older groups. [57]

U.S. COMPLETES WHO WITHDRAWAL

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 response failures and politicization; the U.S. stated it would pursue bilateral global health efforts going forward. [58]

This briefing is informational only and does not constitute medical advice. Sources: CDC Newsroom, WHO News, WHO Disease Outbreak News, openFDA Drugs@FDA, ClinicalTrials.gov, Europe PMC / PubMed.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
  2. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
  3. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic — WHO News
  4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  5. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
  6. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom
  7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  8. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  9. WHO’s response to hantavirus cases linked to a cruise ship — WHO News
  10. Follow-up message by the WHO Director-General to the people of Tenerife regarding the hantavirus response — WHO News
  11. CDC Provides Update on Hantavirus Outbreak Linked to M/V Hondius Cruise Ship — CDC Newsroom
  12. Broader transmission of mpox due to clade Ib MPXV – Global situation — WHO Disease Outbreak News
  13. Mpox: recombinant virus with genomic elements of clades Ib and IIb – Global situation — WHO Disease Outbreak News
  14. Nipah virus disease - India — WHO Disease Outbreak News
  15. Nipah virus infection - Bangladesh — WHO Disease Outbreak News
  16. CDC warns of <em>Listeria</em> outbreak linked to recalled chicken fettuccine alfredo meals — CDC Newsroom
  17. CDC warns of Listeria outbreak linked to requesón/soft ricotta cheese — CDC Newsroom
  18. CDC warns of <em>Salmonella</em> outbreak linked to pistachio cream — CDC Newsroom
  19. CDC announces <em>Salmonella</em> outbreak in 13 states linked to backyard poultry. — CDC Newsroom
  20. UPDATE - Ongoing <em>Salmonella </em>outbreaks linked to backyard poultry sickens 150 more people with over a quarter of — CDC Newsroom
  21. CDC Activates Emergency Operations Center for New World Screwworm Response — CDC Newsroom
  22. CDC Outbreak Update: Infant Botulism Linked to Powdered Infant Formula — CDC Newsroom
  23. AMD1-mediated polyamine metabolism governs tubular repair fate by restraining senescence after kidney injury. — Europe PMC — Longevity
  24. DNA methylation-estimated phenotypes, telomere length, aging and risk of intracranial aneurysms: Evidence from genetic s — Europe PMC — Longevity
  25. Enzymatic and non-enzymatic oxidation of fibrillar collagen. — Europe PMC — Longevity
  26. Combined handgrip strength and incident chronic digestive diseases: a prospective parallel analysis examining broad and — Europe PMC — Longevity
  27. The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis. — Europe PMC — Longevity
  28. Treat the bone, not the fear: antiosteoporosis medications and fracture healing. — Europe PMC — Longevity
  29. Association between intrinsic capacity and disability before death among older adults: a decedent cohort study. — Europe PMC — Longevity
  30. Intrinsic capacity and disability before death: a dynamic relationship. — Europe PMC — Longevity
  31. Maternal diet shapes neonatal microbiome ontogenesis and neurometabolic resilience. — Europe PMC — Longevity
  32. Uric acid alleviates the inflammatory response in LPS-induced BV2 cells and MPTP-induced PD mice by resisting ferroptosi — Europe PMC — Longevity
  33. KEYTRUDA QLEX — MERCK SHARP DOHME — openFDA — Drugs@FDA
  34. KEYTRUDA — MERCK SHARP DOHME — openFDA — Drugs@FDA
  35. WELIREG — MERCK SHARP DOHME — openFDA — Drugs@FDA
  36. TRUQAP — ASTRAZENECA — openFDA — Drugs@FDA
  37. YERVOY — BRISTOL MYERS SQUIBB — openFDA — Drugs@FDA
  38. TZIELD — PROVENTION BIO INC — openFDA — Drugs@FDA
  39. RINVOQ LQ — ABBVIE — openFDA — Drugs@FDA
  40. EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — AUROBINDO PHARMA LIMITED — openFDA — Drugs@FDA
  41. A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer — ClinicalTrials.gov — Aging
  42. Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfa — ClinicalTrials.gov — Aging
  43. Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W — ClinicalTrials.gov — Aging
  44. Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 i — ClinicalTrials.gov — Aging
  45. An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomeruloscleros — ClinicalTrials.gov — Aging
  46. Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi — ClinicalTrials.gov — Aging
  47. A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA) — ClinicalTrials.gov — Aging
  48. Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — ClinicalTrials.gov — Aging
  49. Transnasal Microstream EtCO2 Reduces Hypoxemia During Emergence in Aged Post-Abdomen Surgery — ClinicalTrials.gov — Aging
  50. Comparison of Acceptance and Commitment Therapy and Cognitive Behavior Therapy: Managing Psychological Distress and Its — ClinicalTrials.gov — Aging
  51. CDC's Advisory Committee on Immunization Practices to Meet June 25-26 — CDC Newsroom
  52. CDC's Advisory Committee on Immunization Concludes Meeting with Joint Statement — CDC Newsroom
  53. CDC Immunization Schedule Adopts Individual-Based Decision-Making for COVID-19 and Standalone Vaccination for Chickenpox — CDC Newsroom
  54. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria — CDC Newsroom
  55. CDC Reports Latest National Data on Syphilis in Newborns and Sexually Transmitted Infections (STIs) — CDC Newsroom
  56. CDC Data Show Weekly ER Visits for Tick Bites Higher than Usual — CDC Newsroom
  57. Unsafe food causes 866 million illnesses and 1.5 million deaths annually, young children at highest risk — WHO News
  58. United States Completes WHO Withdrawal — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260618-02-v4 · 2026-06-18 02:02 UTC

Read next